Home/Filings/4/0001209191-21-041041
4//SEC Filing

Reardon Tighe 4

Accession 0001209191-21-041041

CIK 0001817713other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 6:11 PM ET

Size

14.6 KB

Accession

0001209191-21-041041

Insider Transaction Report

Form 4
Period: 2021-06-15
Reardon Tighe
Acting Chief Financial Officer10% Owner
Transactions
  • Conversion

    Common Stock

    2021-06-15+2,696,8432,696,843 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-06-15+1,153,2383,850,081 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-06-15$17.00/sh+629,411$10,699,9874,479,492 total(indirect: See footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2021-06-15900,2640 total(indirect: See footnote)
    Common Stock (1,153,238 underlying)
  • Conversion

    Series A Convertible Preferred Stock

    2021-06-152,105,2640 total(indirect: See footnote)
    Common Stock (2,696,843 underlying)
Holdings
  • Common Stock

    172,935
Footnotes (3)
  • [F1]Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
  • [F2]Shares are held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Mr. Reardon is Chief Financial Officer of Avalon Ventures and shares voting and investment power with respect to the shares held by ABV SPV. Mr. Reardon disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. if any.
  • [F3]The shares were purchased in the Issuer's initial public offering.

Issuer

Janux Therapeutics, Inc.

CIK 0001817713

Entity typeother

Related Parties

1
  • filerCIK 0001760431

Filing Metadata

Form type
4
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 6:11 PM ET
Size
14.6 KB